The efficacy and safety of amifostine for the acute radiation syndrome

References

• Ferguson CD, Potter WC, Sands A, et al. The four faces of nuclear terrorism. Monterey, CA: Center for Nonproliferation Studies, Monterey Institute of International Studies Nuclear Threat Initiative; 2004.
   Google Scholar
• Pellmar TC, Rockwell S. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res. 2005;163:115–123.
   PubMedGoogle Scholar
• Coleman CN, Blakely WF, Fike JR, et al. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17- 18,2001. Radiat Res. 2003;159:812–834.
   PubMedGoogle Scholar
• Benjamin GC, McGeary M, McCutchen SR. Assessing medical preparedness to respond to a terrorist nuclear event: workshop report. Washington, DC: The National Academies Press; 2009.
   Google Scholar
• Stone HB, Moulder JE, Coleman CN, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3- 4, 2003. Radiat Res. 2004;162:711–728.
   PubMed Web of Science ®Google Scholar
• Seed TM. Radiation protectants: current status and future prospects. Health Phys. 2005;89:531–545.
   PubMed Web of Science ®Google Scholar
• Singh VK, Garcia M, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status. Int J Radiat Biol. 2017;93:870–884.
   PubMed Web of Science ®Google Scholar
• Singh VK, Hanlon BK, Santiago PT, et al. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with ‘standard of care’ medicinal and procedures not requiring regulatory approval for use. Int J Radiat Biol. 2017;93:885–906.
   PubMed Web of Science ®Google Scholar
• Singh VK, Newman VL, Romaine PL, et al. Radiation countermeasure agents: an update (2011–2014). Expert Opin Ther Pat. 2014;24:1229–1255.
   PubMed Web of Science ®Google Scholar
• Yahyapour R, Shabeeb D, Cheki M, et al. Radiation protection and mitigation by natural antioxidants and flavonoids: implications to radiotherapy and radiation disasters. Curr Mol Pharmacol. 2018;11:285–304.
   PubMed Web of Science ®Google Scholar
• Singh VK, Santiago PT, MacVittie TJ. Opportunities and challenges with animal models for acute radiation syndrome drug discovery. Expert Opin Drug Discov. 2018;13:987–992.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves Neupogen for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident. 2015. [cited 2016 July 6]. Available from: http://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/AboutMCMi/ucm443245.htm
   Google Scholar
• National Institute of Allergic and Infectious Diseases. Pegfilgrastim approved for treating acute radiation syndrome. 2015; [cited 2016 Aug 18]. Available from: https://www.niaid.nih.gov/topics/radnuc/Pages/pegfilgrastim.aspx.
   Google Scholar
• U.S. Food and drug Administration. FDA approves Leukine for acute radiation syndrome. 2018. [cited 2018 Apr 01]. Available from: https://www.fda.gov/downloads/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/AboutMCMi/UCM603226.pdf.
   Google Scholar
• Hankey KG, Farese AM, Blaauw EC, et al. Pegfilgrastim improves survival of lethally irradiated nonhuman primates. Radiat Res. 2015;183:643–655.
   PubMed Web of Science ®Google Scholar
• Farese AM, MacVittie TJ. Filgrastim for the treatment of hematopoietic acute radiation syndrome. Drugs Today (Barc). 2015;51:537–548.
   PubMed Web of Science ®Google Scholar
• Singh VK, Seed TM. An update on sargramostim for treatment of acute radiation syndrome. Drugs Today (Barc). 2018;54:679–693.
   PubMed Web of Science ®Google Scholar
• Singh VK, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures. Int J Radiat Biol. 2017;93:851–869.
   PubMed Web of Science ®Google Scholar
• Andreassen CN, Grau C, Lindegaard JC. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol. 2003;13:62–72.
   PubMed Web of Science ®Google Scholar
• Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 1999;26:3–21.
   PubMed Web of Science ®Google Scholar
• Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol. 2000;72:425–435.
   PubMed Web of Science ®Google Scholar
• Capizzi RL. Clinical status and optimal use of amifostine. Oncology (Williston Park). 1999;13: 47–59. discussion 63, 67.
   PubMed Web of Science ®Google Scholar
• Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:357–364.
   PubMed Web of Science ®Google Scholar
• Gu J, Zhu S, Li X, et al. Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials. PLoS One. 2014;9:e95968.
   PubMed Web of Science ®Google Scholar
• Piper JR, Stringfellow CR Jr., Elliott RD, et al. S-2-(omega-aminoalkylamino)ethyl dihydrogen phosphorothioates and related compounds as potential antiradiation agents. J Med Chem. 1969;12:236–243.
   PubMed Web of Science ®Google Scholar
• Davidson DE, Grenan MM, Sweeney TR. Biological characteristics of some improved radioprotectors. In: Brady LW, editor. Radiation sensitizers, their use in the clinical management of cancer. New York, Masson: Masson Publishing; 1980. p. 309–320.
   Google Scholar
• Brown DQ, Graham WJ 3rd, MacKenzie LJ, et al. Can WR-2721 be improved upon? Pharmacol Ther. 1988;39:157–168.
   PubMed Web of Science ®Google Scholar
• Giambrarresi LI, Walker RI. Prospects of radioprotection. In: Office of the Surgeon General DotA, United States of America, editor. Medical consequences of nuclear warfare. Falls Church, VA: TMM Publications. 1989. p. 245–273.
   Google Scholar
• Grdina DJ, Kataoka Y, Murley JS. Amifostine: mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol Drug Interact. 2000;16:237–279.
   PubMedGoogle Scholar
• Ryan SV, Carrithers SL, Parkinson SJ, et al. Hypotensive mechanisms of amifostine. J Clin Pharmacol. 1996;36:365–373.
   PubMed Web of Science ®Google Scholar
• Turrisi AT, Glover DJ, Hurwitz S, et al. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]. Cancer Treat Rep 1986;70:1389–1393
   PubMedGoogle Scholar
• Landauer MR, Davis HD, Dominitz JA, et al. Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice. Pharmacol Biochem Behav. 1987;27:573–576.
   PubMed Web of Science ®Google Scholar
• Landauer MR, Davis HD, Dominitz JA, et al. Long-term effects of radioprotector WR-2721 on locomotor activity and body weight of mice following exposure to ionizing radiation. Toxicology. 1988;49:315–323.
   PubMed Web of Science ®Google Scholar
• Landauer MR, Davis HD, Dominitz JA, et al. Comparative behavioral toxicity of four sulfhydryl radioprotective compounds in mice: WR-2721, cysteamine, diethyldithiocarbamate, and N-acetylcysteine. Pharmacol Ther. 1988;39:97–100.
   PubMed Web of Science ®Google Scholar
• Dorr RT. Radioprotectants: pharmacology and clinical applications of amifostine. Semin Radiat Oncol. 1998;8:10–13.
   PubMed Web of Science ®Google Scholar
• Weiss JF. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Perspect. 1997;105(Suppl 6):1473–1478.
   PubMedGoogle Scholar
• Seed TM, Fry SA, Neta R, et al. Prevention and treatments: summary statement. Mil Med. 2002;167:87–93.
   PubMedGoogle Scholar
• Roberts JT, Priestman TJ. A review of ondansetron in the management of radiotherapy-induced emesis. Oncology. 1993;50:173–179.
   PubMed Web of Science ®Google Scholar
• Cumberland Pharmaceuticals Inc. ETHYOL- amifostine injection, powder, lyophilized, for solution. 2017. [cited 2018 Oct 28]. Available from: file:///C:/Users/vsingh/Downloads/20170606_f11c0753-ef0a-4e1b-83dd-8543649df9a5.pdf.
   Google Scholar
• Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–3345.
   PubMed Web of Science ®Google Scholar
• Ferraiolo DM, Veitz-Keenan A. Insufficient evidence for interventions to prevent dry mouth and salivary gland dysfunction post head and neck radiotherapy. Evid Based Dent. 2018;19:30–31.
   PubMedGoogle Scholar
• Weiss JF, Landauer MR. History and development of radiation-protective agents. Int J Radiat Biol. 2009;85:539–573.
   PubMed Web of Science ®Google Scholar
• Murray D, McBride WH. Radioprotective agents. In: Kirk-Othmer, editor. Kirk-Othmer encyclopedia of chemical technology. New York: John Wiley & Sons, Inc; 1996. p. 63–1006.
   Google Scholar
• Ziegler DM, Duffel MW, Pulsen LL. Studies on the nature and regulation of the cellular thiol: disulphide potential. In: Elliott K, Whelan J, eds. Ciba Foundation Symposium on Sulphur in Biology - Novartis Foundation Symposia; Amsterdam: Excerpta Medica; 1980. p. 191–204
   Google Scholar
• Weiss JF, Kumar KS. Antioxidant mechanisms in radiation injury and radioprotection. In: Chow CK, editor. Cellular antioxidant defense mechanisms. Boca Raton, FL: CRC Press; 1988. p. 163–189.
   Google Scholar
• Spencer CM, Goa KL. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs. 1995;50:1001–1031.
   PubMed Web of Science ®Google Scholar
• Giambarresi LI, Walker RI. Prospects for radioprotection. In: Zajtchuk R, Jenkins DP, Bellamy RF, editors. Textbook of military medicine, part II, medical consequences of nuclear warfare. Falls Church, VA: TMM Publications, Office of the Surgeon General; 1996. p. 276–303.
   Google Scholar
• Yuhas JM, Storer JB. Chemoprotection against three modes of radiation death in the mouse. Int J Radiat Biol Relat Stud Phys Chem Med. 1969;15:233–237.
   PubMed Web of Science ®Google Scholar
• Sigdestad CP, Connor AM, Scott RM. The effect of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) on intestinal crypt survival. I. 4 MeV x-rays. Radiat Res. 1975;62:267–275.
   PubMed Web of Science ®Google Scholar
• Rasey JS, Nelson NJ, Mahler P, et al. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution. Radiat Res. 1984;97:598–607.
   PubMed Web of Science ®Google Scholar
• Brown DQ, Pittock JW 3rd, Rubinstein JS. Early results of the screening program for radioprotectors. Int J Radiat Oncol Biol Phys. 1982;8:565–570.
   PubMed Web of Science ®Google Scholar
• Doherty DG, Burnett WT Jr., Shapira R. Chemical protection against ionizing radiation. II. Mercaptoalkylamines and related compounds with protective activity. Radiat Res. 1957;7:13–21.
   PubMed Web of Science ®Google Scholar
• Kuna P. Duration and degree of radioprotection of WR-2721 in mice following its intraperitoneal, intramuscular and subcutaneous administration. Radiobiol Radiother (Berl). 1983;24:357–364.
   PubMedGoogle Scholar
• Sigdestad CP, Grdina DJ, Connor AM, et al. A comparison of radioprotection from three neutron sources and 60Co by WR-2721 and WR-151327. Radiat Res. 1986;106:224–233.
   PubMed Web of Science ®Google Scholar
• Wilmore BH, Cassidy PB, Warters RL, et al. Thiazolidine prodrugs as protective agents against gamma-radiation-induced toxicity and mutagenesis in V79 cells. J Med Chem. 2001;44:2661–2666.
   PubMed Web of Science ®Google Scholar
• Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27–31.
   PubMedGoogle Scholar
• Santini V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother. 2001;2:479–489.
   PubMedGoogle Scholar
• Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 2007;12:738–747.
   PubMed Web of Science ®Google Scholar
• Purdie JW, Inhaber ER, Schneider H, et al. Interaction of cultured mammalian cells with WR-2721 and its thiol, WR-1065: implications for mechanisms of radioprotection. Int J Radiat Biol Relat Stud Phys Chem Med. 1983;43:517–527.
   PubMed Web of Science ®Google Scholar
• Glover D, Negendank W, Delivoria-Papadopoulos M, et al. Alterations in oxygen transport following WR-2721. Int J Radiat Oncol Biol Phys. 1984;10:1565–1568.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Zois CE, et al. Normal tissue radioprotection by amifostine via Warburg-type effects. Sci Rep. 2016;6:30986.
   PubMed Web of Science ®Google Scholar
• Savoye C, Swenberg C, Hugot S, et al. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int J Radiat Biol. 1997;71:193–202.
   PubMed Web of Science ®Google Scholar
• Rubin DB, Drab EA, Kang HJ, et al. WR-1065 and radioprotection of vascular endothelial cells. I. Cell proliferation, DNA synthesis and damage. Radiat Res. 1996;145:210–216.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485–490.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Eguchi Y, Kamiike W, et al. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res. 1996;56:2161–2166.
   PubMed Web of Science ®Google Scholar
• Grdina DJ, Murley JS, Kataoka Y. Radioprotectants: current status and new directions. Oncology. 2002;63(Suppl 2):2–10.
   PubMed Web of Science ®Google Scholar
• Grdina DJ, Murley JS, Kataoka Y, et al. Radioprotectors: current status and new directions. Radiat Res. 2005;163:704–705.
   PubMed Web of Science ®Google Scholar
• Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 1980;40:1519–1524.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs. 2002;13:181–209.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Weiss JF, Kumar KS. Radioprotection by combination of WR-151327, vitamin E and selenomethionine. 40th Annual Meeting of the Radiation Research Society; Salt Lake City UT: Radiation Research Society; 1992
   Google Scholar
• Singh VK, Fatanmi OO, Wise SY, et al. The potentiation of the radioprotective efficacy of two medical countermeasures, gamma-tocotrienol and amifostine, by a combination prophylactic modality. Radiat Prot Dosimetry. 2016;172:302–310.
   PubMed Web of Science ®Google Scholar
• Grdina DJ, Murley JS, Kataoka Y, et al. Relationships between cytoprotection and mutation prevention by WR-1065. Mil Med. 2002;167:51–53.
   PubMedGoogle Scholar
• Seed TM, Inal CE, Singh VK. Radioprotection of hematopoietic progenitors by low dose amifostine prophylaxis. Int J Radiat Biol. 2014;90:594–604.
   PubMed Web of Science ®Google Scholar
• Fatome M, Courteille F, Laval JD, et al. Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration. Int J Radiat Biol Relat Stud Phys Chem Med. 1987;52:21–29.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pendergrass JA Jr., Kumar KS, et al. Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. Int J Radiat Biol. 2002;78:535–543.
   PubMed Web of Science ®Google Scholar
• Pamujula S, Graves RA, Freeman T, et al. Oral delivery of spray dried PLGA/amifostine nanoparticles. J Pharm Pharmacol. 2004;56:1119–1125.
   PubMed Web of Science ®Google Scholar
• Steel-Goodwin L, Egan JE, Kendrick JM, et al. Comparative intestinal and testes toxicity of four aminothiols in irradiated and nonirradiated mice. Ann Clin Lab Sci. 1993;23:439–447.
   PubMed Web of Science ®Google Scholar
• Weiss JF, Kumar KS, Srinivasan V, et al. Comparison of toxicity and radioprotective efficacy of WR-2721 and WR-3689 in mice. Proc Am Assoc Can Res. 1990;31:433.
   Google Scholar
• Peebles DD, Soref CM, Copp RR, et al. ROS-scavenger and radioprotective efficacy of the new PrC-210 aminothiol. Radiat Res. 2012;178:57–68.
   PubMed Web of Science ®Google Scholar
• Copp RR, Peebles DD, Soref CM, et al. Radioprotective efficacy and toxicity of a new family of aminothiol analogs. Int J Radiat Biol. 2013;89:485–492.
   PubMed Web of Science ®Google Scholar
• Soref CM, Hacker TA, Fahl WE. A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses. Int J Radiat Oncol Biol Phys. 2012;82:e701–7.
   PubMed Web of Science ®Google Scholar
• Oiry J, Pue JY, Imbach JL, et al. Synthesis and radioprotective activity of new cysteamine and cystamine derivatives. J Med Chem. 1986;29:2217–2225.
   PubMed Web of Science ®Google Scholar
• Soni R, Arora A, Singh S, et al. Radio-modifying effects of amifostine analogues in whole body gamma irradiated mice. International Conference on Radiation Biology: Frontiers in Radiobiology: Immunomodulation, Countermeasures & Therapeutics; Nov 11-13; New Delhi, India; 2014.
   Google Scholar
• Gautam A, Gupta A, Lomash V, et al. Prophylactic efficacy of combination of DRDE-07 and its analogues with amifostine against sulphur mustard induced systemic toxicity. Indian J Exp Biol. 2010;48:752–761.
   PubMed Web of Science ®Google Scholar
• Kulkarni AS, Vijayaraghavan R, Anshoo G, et al. Evaluation of analogues of DRDE-07 as prophylactic agents against the lethality and toxicity of sulfur mustard administered through percutaneous route. J Appl Toxicol. 2006;26:115–125.
   PubMed Web of Science ®Google Scholar
• Arora A, Bhuria V, Hazari PP, et al. Amifostine analog, DRDE-30, attenuates bleomycin-induced pulmonary fibrosis in mice. Front Pharmacol. 2018;9:394.
   PubMed Web of Science ®Google Scholar
• Xie J, Wang C, Zhao F, et al. Application of multifunctional nanomaterials in radioprotection of healthy tissues. Adv Healthc Mater. 2018;7:e1800421.
   PubMed Web of Science ®Google Scholar
• Pamujula S, Kishore V, Rider B, et al. Radioprotection in mice following oral delivery of amifostine nanoparticles. Int J Radiat Biol. 2005;81:251–257.
   PubMed Web of Science ®Google Scholar
• Pamujula S, Kishore V, Rider B, et al. Radioprotection in mice following oral administration of WR-1065/PLGA nanoparticles. Int J Radiat Biol. 2008;84:900–908.
   PubMed Web of Science ®Google Scholar
• Li WM, Chiang CS, Huang WC, et al. Amifostine-conjugated pH-sensitive calcium phosphate-covered magnetic-amphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer. J Control Release. 2015;220:107–118.
   PubMed Web of Science ®Google Scholar
• Kolate A, Baradia D, Patil S, et al. PEG - a versatile conjugating ligand for drugs and drug delivery systems. J Control Release. 2014;192:67–81.
   PubMed Web of Science ®Google Scholar
• Yang X, Ding Y, Ji T, et al. Improvement of the in vitro safety profile and cytoprotective efficacy of amifostine against chemotherapy by PEGylation strategy. Biochem Pharmacol. 2016;108:11–21.
   PubMed Web of Science ®Google Scholar
• Patchen ML, MacVittie TJ. Granulocyte colony-stimulating factor and amifostine (Ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol. 1994;21:26–32.
   PubMed Web of Science ®Google Scholar
• Patchen ML, MacVittie TJ, Solberg BD, et al. Radioprotection by polysaccharides alone and in combination with aminothiols. Adv Space Res. 1992;12:233–248.
   PubMedGoogle Scholar
• Bardet E, Martin L, Calais G, et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol. 2002;29:57–60.
   PubMed Web of Science ®Google Scholar
• Mahmood J, Jelveh S, Zaidi A, et al. Targeting the Renin-angiotensin system combined with an antioxidant is highly effective in mitigating radiation-induced lung damage. Int J Radiat Oncol Biol Phys. 2014;89:722–728.
   PubMed Web of Science ®Google Scholar
• Hirouchi T, Ito K, Nakano M, et al. Mitigative effects of a combination of multiple pharmaceutical drugs on the survival of mice exposed to lethal ionizing radiation. Curr Pharm Biotechnol. 2015;17:190–199.
   PubMed Web of Science ®Google Scholar
• Fish BL, Gao F, Narayanan J, et al. Combined hydration and antibiotics with lisinopril to mitigate acute and delayed high-dose radiation injuries to multiple organs. Health Phys. 2016;111:410–419.
   PubMed Web of Science ®Google Scholar
• Plett PA, Chua HL, Sampson CH, et al. PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys. 2014;106:7–20.
   PubMed Web of Science ®Google Scholar
• Cox G. Improving survival in a mouse H-ARS model using combinations of hematopoietic growth factors and an ACE inhibitor. A poly-pharmacy approach to mitigate acute radiation syndrome (ARS). Rockville, MD: National Institute of Allergy and Infectious Diseases, National Institutes of Health.
   Google Scholar
• Seed TM, Inal CE, Deen JE. Assessment of a combined G-CSF plus IL-11 cytokine treatment for radiation-induced hematopoietic injury. Proceeding of the 48th Annual Meeting of the Radiation Research Society; San Juan, Puerto Rico; 2001. p. 161
   Google Scholar
• Medhora M. 2018. Enhanced mitigation of radiation-induced injuries by combining angiotensin-converting enzyme (ACE) inhibitors with other countermeasures. A poly-pharmacy approach to mitigate acute radiation syndrome (ARS). Rockville, MD: National Institute of Allergy and Infectious Diseases, National Institutes of Health.
   Google Scholar
• Hofer M, Hoferova Z, Depes D, et al. Combining pharmacological countermeasures to attenuate the acute radiation syndrome -A concise review. In: Molecules. 2017;22.
   PubMed Web of Science ®Google Scholar
• Hofer M, Falk M, Komurkova D, et al. Two new faces of amifostine: protector from DNA damage in normal cells and inhibitor of DNA repair in cancer cells. J Med Chem. 2016;59:3003–3017.
   PubMed Web of Science ®Google Scholar
• Patchen ML. Amifostine plus granulocyte colony-stimulating factor therapy enhances recovery from supralethal radiation exposures: preclinical experience in animals models. Eur J Cancer. 1995;31A:S17–21.
   PubMed Web of Science ®Google Scholar
• Patchen ML, MacVittie TJ, Souza LM. Post-irradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. Int J Radiat Oncol Biol Phys. 1992;22:773–779.
   PubMed Web of Science ®Google Scholar
• Neumeister P, Jaeger G, Eibl M, et al. Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome. Leuk Lymphoma. 2001;40:345–349.
   PubMed Web of Science ®Google Scholar
• Winczura P, Jassem J. Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev. 2010;36:268–275.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Weiss JF. Radioprotection by vitamin E: injectable vitamin E administered alone or with WR-3689 enhances survival of irradiated mice. Int J Radiat Oncol Biol Phys. 1992;23:841–845.
   PubMed Web of Science ®Google Scholar
• Weiss JF, Hoover RL, Kumar KS. Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of WR-2721. Free Radic Res Commun. 1987;3:33–38.
   PubMedGoogle Scholar
• Kaplan B, Orhan O, Yazici C, et al. Radioprotective effects of amifostine (WR 2721) and vitamin E on whole-body-irradiated rat liver. Turk Klin Tip Bilim Derg. 2009;29:1055–1062.
   Google Scholar
• Singh VK, Hauer-Jensen M. Gamma-tocotrienol as a promising countermeasure for acute radiation syndrome: current status. Int J Mol Sci. 2016;17:e663.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Singh PK, Ghosh SP, et al. Granulocyte colony-stimulating factor antibody abrogates radioprotective efficacy of gamma-tocotrienol, a promising radiation countermeasure. Cytokine. 2013;62:278–285.
   PubMed Web of Science ®Google Scholar
• Miller RC, Murley JS, Grdina DJ. Metformin exhibits radiation countermeasures efficacy when used alone or in combination with sulfhydryl containing drugs. Radiat Res. 2014;181:464–470.
   PubMed Web of Science ®Google Scholar
• Xu G, Wu H, Zhang J, et al. Metformin ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice. Free Radic Biol Med. 2015;87:15–25.
   PubMed Web of Science ®Google Scholar
• Kumar KS, Vaishnav YN, Weiss JF. Radioprotection by antioxidant enzymes and enzyme mimetics. Pharmacol Ther. 1988;39:301–309.
   PubMed Web of Science ®Google Scholar
• Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol. 2006;44:1173–1183.
   PubMed Web of Science ®Google Scholar
• Hanson WR. Radiation protection of murine intestine by WR-2721, 16,16-dimethyl prostaglandin E2, and the combination of both agents. Radiat Res. 1987;111:361–373.
   PubMed Web of Science ®Google Scholar
• Hanson WR, Houseman KA, Collins PW. Radiation protection in vivo by prostaglandins and related compounds of the arachidonic acid cascade. Pharmacol Ther. 1988;39:347–356.
   PubMed Web of Science ®Google Scholar
• Mota JM, Soares PM, Menezes AA, et al. Amifostine (Wr-2721) prevents indomethacin-induced gastric damage in rats: role of non-protein sulfhydryl groups and leukocyte adherence. Dig Dis Sci. 2007;52:119–125.
   PubMed Web of Science ®Google Scholar
• Lu L, Pelus LM, Broxmeyer HE. Modulation of the expression of HLA-DR (Ia) antigens and the proliferation of human erythroid (BFU-E) and multipotential (CFU-GEMM) progenitor cells by prostaglandin E. Exp Hematol. 1984;12:741–748.
   PubMed Web of Science ®Google Scholar
• Hoggatt J, Singh P, Sampath J, et al. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood. 2009;113:5444–5455.
   PubMed Web of Science ®Google Scholar
• Patchen ML, MacVittie TJ, Jackson WE. Postirradiation glucan administration enhances the radioprotective effects of WR-2721. Radiat Res. 1989;117:59–69.
   PubMed Web of Science ®Google Scholar
• Patchen ML, MacVittie TJ, Weiss JF. Combined modality radioprotection: the use of glucan and selenium with WR-2721. Int J Radiat Oncol Biol Phys. 1990;18:1069–1075.
   PubMed Web of Science ®Google Scholar
• Pillai TG, Uma Devi P. Mushroom beta glucan: potential candidate for post irradiation protection. Mutat Res. 2013;751:109–115.
   PubMed Web of Science ®Google Scholar
• Fedorocko P, Brezani P, Mackova NO. Radioprotective effects of WR-2721, Broncho-Vaxom and their combinations: survival, myelopoietic restoration and induction of colony-stimulating activity in mice. Int J Immunopharmacol. 1994;16:177–184.
   PubMed Web of Science ®Google Scholar
• Mackova NO, Fedorocko P. Combined radioprotective effect of Broncho-Vaxom and WR-2721 on hemopoiesis and circulating blood cells. Neoplasma. 1995;42:25–30.
   PubMed Web of Science ®Google Scholar
• Jiang S, Shen X, Liu Y, et al. Radioprotective effects of Sipunculus nudus L. polysaccharide combined with WR-2721, rhIL-11 and rhG-CSF on radiation-injured mice. J Radiat Res. 2015;56:515–522.
   PubMed Web of Science ®Google Scholar
• Liu W, Chen Q, Wu S, et al. Radioprotector WR-2721 and mitigating peptidoglycan synergistically promote mouse survival through the amelioration of intestinal and bone marrow damage. J Radiat Res. 2015;56:278–286.
   PubMed Web of Science ®Google Scholar
• Seed T, Singh VK, Hanlon BK. Early and late changes in radiation‑induced gene expression arrays following radioprotection with amifostine. J Radiat Cancer Res. 2019;10:44–57.
   Google Scholar
• Koukourakis MI, Simopoulos C, Minopoulos G, et al. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. Clin Cancer Res. 2003;9:3288–3293.
   PubMed Web of Science ®Google Scholar
• Praetorius NP, Mandal TK. Alternate delivery route for amifostine as a radio-/chemo-protecting agent. J Pharm Pharmacol. 2008;60:809–815.
   PubMed Web of Science ®Google Scholar
• Weiss JF, Landauer MR. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology. 2003;189:1–20.
   PubMed Web of Science ®Google Scholar